Antiretroviral prophylaxis for breastfeeding transmission in Malawi: Drug concentrations, virological efficacy and safety

Antiviral Therapy

Volumn 17, Issue 8, 2012, Pages 1511-1519

  Palombi, Leonardo ^a,b   Pirillo, Maria F ^c   Andreotti, Mauro ^c   Liotta, Giuseppe ^a,b   Erba, Fulvio ^a,b   Sagno, Jean Baptiste ^d   Maulidi, Martin ^d   Ceffa, Susanna ^b   Jere, Haswell ^d   Marchei, Emilia ^c   Pichini, Simona ^c   Galluzzo, Clementina M ^c   Marazzi, Maria C ^e   Vella, Stefano ^c   Giuliano, Marina ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b DREAM Program   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d DREAM Program   (Malawi)

^e LUMSA UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BLOOD SAMPLING; BREAST FEEDING; BREAST MILK; DELIVERY; DIARRHEA; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MILK LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GESTATION PERIOD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALARIA; MALAWI; MASS SPECTROMETRY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PUERPERIUM; SIDE EFFECT; VIROLOGY; VIRUS LOAD; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; BREAST FEEDING; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALAWI; MALE; PREGNANCY; PREMEDICATION; VIRAL LOAD; YOUNG ADULT;

EID: 84871914614     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2315     Document Type: Article

References (23)

1. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. (Updated 2010. Accessed 26 July 2012.) Available from http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html
2. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119-129. (Pubitemid 351962035)
3. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-2281.
4. Shapiro RL, Hughes MD, Ogwy A, et al. Antiretroviral regimens in pregnancy and breastfeeding in Botswana. N Engl J Med 2010; 362:2282-2294.
5. The Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-180.
6. Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-Saharan Africa with maternal use of highly active antiretroviral during breastfeeding. Pediatr Infect Dis J 2009; 28:483-487.
7. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-163.
8. Rezk NL, White N, Bridges AS, et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometry method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit 2008; 30:611-619.
9. Marchei E, Escuder D, Pallas CR, et al. Simultaneous analysis of frequently used licit and illicit psychoactive drugs in breast milk by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2011; 55:309-316.
10. Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0. National Institute of Health. (Updated December 2004. Accessed December 2011.) Available from http://rsc.tech-res.com/document/safetyandpharamcovigilance/Table-for-Grading- Severity-of-Adult-Pediatric-Adverse-Events.pdf
11. Chibwesha CJ, Giganti MJ, Putta N, et al. Optimal time on HAART for prevention of mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 2011; 58:224-228.
12. Hudelson SE, McConnell MS, Bagenda D, et al. Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration. AIDS 2010; 24:557-561.
13. Llibre JM, Arribas JR, Domingo P, et al. Clinical implications of fixed dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 2011; 25:1683-1690.
14. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breastfeeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720-727. (Pubitemid 41193069)
15. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53:1170-1176.
16. Schneider S, Peltier A, Grass A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008; 48:450-454.
17. Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005; 11:127-129. (Pubitemid 40321346)
18. Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr 2011; 56:428-436.
19. Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011; 57:290-296.
20. Lubega IR, Fowler MG, Musoke P, et al. Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy Malawian and Ugandan infants. J Acquir Immune Defic Syndr 2010; 55:58-64.
21. Bae WH, Wester C, Smeaton L, et al. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. AIDS 2008; 22:1633-1640.
22. Zeh C, Weidle P, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of tripleantiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.
23. Fogel J, Li Q, Taha T, et al. Initiation of antiretroviral treatment in women after delivery can induce multi drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52:1069-1076.